Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

IANALUMAB PROLONGED THE DURATION OF SAFE PLATELET LEVELS DURING AND AFTER TREATMENT IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) PREVIOUSLY TREATED WITH CORTICOSTEROIDS 1,2 PATIENTS TREATED WITH IANALUMAB ALSO EXPERIENCED A SIGNIFICANTLY HIGHER RATE OF SUSTAINED IMPROVEMENTS IN PLATELET COUNT, THE KEY SECONDARY ENDPOINT OF THE STUDY 1 IANALUMAB, ADMINISTERED AS FOUR ONCE-MONTHLY DOSES IN THE ITP SETTING, COULD OFFER LONG-TERM DISEASE CONTROL THROUGH A SHORT COURSE OF TREATMENT AND POTENTIALLY ALLOW PATIENTS EXTENDED TIME OFF TREATMENT, IF APPROVED DATA EXPECTED TO BE PRESENTED AT AN UPCOMING MEDICAL MEETING AND INCLUDED IN FUTURE REGULATORY SUBMISSIONS IN 2027 ALONG WITH RESULTS FROM THE ONGOING FIRST-LINE ITP TRIAL,VAYHIT1 BASEL, AUGUST 12, 2025  NOVARTIS TODAY ANNOUNCED POSITIVE TOP-LINE RESULTS FROM VAYHIT2, A PHASEIII TRIAL EVALUATING IANALUMAB PLUS ELTROMBOPAG IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) PREVIOUSLY TREATED WITH CORTICOSTEROIDS1,2. IANALUMAB PLUS ELTROMBOPAG, COMPARED TO PLACEBO PLUS ELTROMBOPAG, SIGNIFICANTLY PROLONGED THE TIME TO TREATMENT FAILURE (TTF), THE PRIMARY ENDPOINT THAT ASSESSES HOW LONG PATIENTS MAINTAIN SAFE PLATELET LEVELS DURING AND AFTER THE TREATMENT PERIOD1,2.

NOVARTIS IANALUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN ITP, DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT IN TIME TO TREATMENT FAILURE

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR NEPTUNUS-1 AND NEPTUNUS-2 ARE THE FIRST EVER GLOBAL PHASE III TRIALS TO DEMONSTRATE STATISTICALLY SIGNIFICANT REDUCTION IN DISEASE ACTIVITY FOR SJGREN'S DISEASE1 IANALUMAB HAS THE POTENTIAL TO BECOME THE FIRST AND ONLY TARGETED TREATMENT APPROVED FOR PATIENTS WITH SJGREN'S DISEASE IANALUMAB WAS WELL TOLERATED AND DEMONSTRATED A FAVORABLE SAFETY PROFILE IN SJGREN'S DISEASE1,2 NOVARTIS PLANS TO PRESENT ITS DATA AT AN UPCOMING MEDICAL CONGRESS AND SUBMIT TO HEALTH AUTHORITIES GLOBALLY EAST HANOVER, N.J.

NOVARTIS ANNOUNCES BOTH IANALUMAB PHASE III CLINICAL TRIALS MET PRIMARY ENDPOINT IN PATIENTS WITH SJGREN'S DISEASE

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR NEPTUNUS-1 AND NEPTUNUS-2 ARE THE FIRST EVER GLOBAL PHASE III TRIALS TO DEMONSTRATE STATISTICALLY SIGNIFICANT REDUCTION IN DISEASE ACTIVITY FOR SJGREN'S DISEASE 1  IANALUMAB HAS THE POTENTIAL TO BECOME THE FIRST AND ONLY TARGETED TREATMENT APPROVED FOR PATIENTS WITH SJGREN'S DISEASE IANALUMAB WAS WELL TOLERATED AND DEMONSTRATED A FAVORABLE SAFETY PROFILE IN SJGREN'S DISEASE 1, 2 NOVARTIS PLANS TO PRESENT ITS DATA AT AN UPCOMING MEDICAL CONGRESS AND SUBMIT TO HEALTH AUTHORITIES GLOBALLY BASEL, AUGUST 11, 2025  NOVARTIS TODAY ANNOUNCED POSITIVE TOP-LINE RESULTS FROM ITS PHASE III TRIALS EVALUATING IANALUMAB (VAY736) IN ADULTS WITH ACTIVE SJGREN'S DISEASE.

LEQVIO CAN NOW BE USED ALONE, WITHOUT ADDITION OF STATIN THERAPY, AS ADJUNCT TO DIET AND EXERCISE FOR LDL-C REDUCTION IN PATIENTS WITH HYPERCHOLESTEROLEMIA (HIGH LDL-C)1 4 OUT OF 5 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) PATIENTS DO NOT REACH GUIDELINE-RECOMMENDED LDL-C TARGET, REINFORCING URGENT NEED FOR MORE AGGRESSIVE LDL-C LOWERING2-5 TWICE-YEARLY LEQVIO IS UNIQUELY POSITIONED TO HELP SUPPORT PATIENT ADHERENCE AND LONG-TERM LDL-C MANAGEMENT, INCLUDING GOAL ATTAINMENT EAST HANOVER, N.J. , JULY 31, 2025 /PRNEWSWIRE/ -- NOVARTIS ANNOUNCED TODAY THAT THE US FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED A LABEL UPDATE FOR LEQVIO (INCLISIRAN), ENABLING ITS USE AS MONOTHERAPY ALONG WITH DIET AND EXERCISE TO REDUCE LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) IN ADULTS WITH HYPERCHOLESTEROLEMIA1.

NOVARTIS TWICE-YEARLY* LEQVIO (INCLISIRAN) RECEIVES FDA APPROVAL FOR NEW INDICATION ENABLING FIRST-LINE USE

MATCHPOINT TO RECEIVE UP TO $60 MILLION IN UPFRONT PAYMENT AND RESEARCH FUNDING, WITH UP TO $1 BILLION IN TOTAL POTENTIAL PAYMENTS, INCLUDING OPTION EXERCISE FEE, DEVELOPMENT AND COMMERCIAL MILESTONES MATCHPOINT WILL LEAD ALL RESEARCH ACTIVITIES THROUGH DEVELOPMENT CANDIDATE SELECTION WATERTOWN, MASS., JULY 24, 2025 (GLOBE NEWSWIRE) -- MATCHPOINT THERAPEUTICS, A BIOTECHNOLOGY COMPANY PIONEERING THE DISCOVERY OF PRECISION COVALENT MEDICINES, TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN EXCLUSIVE OPTION AND LICENSE AGREEMENT WITH NOVARTIS FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ORAL COVALENT INHIBITORS DIRECTED AT A TRANSCRIPTION FACTOR LINKED TO A NUMBER OF INFLAMMATORY DISEASES.

MATCHPOINT THERAPEUTICS ANNOUNCES EXCLUSIVE OPTION AND LICENSE AGREEMENT WITH NOVARTIS TO DEVELOP ORAL INHIBITORS FOR MULTIPLE INFLAMMATORY DISEASES

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR MUKUL MEHTA, CURRENTLY HEAD OF BUSINESS PLANNING AND ANALYSIS (BPA), DIGITAL FINANCE AND TAX, HAS BEEN APPOINTED CHIEF FINANCIAL OFFICER, EFFECTIVE MARCH 16, 2026, AND WILL JOIN THE EXECUTIVE COMMITTEE (ECN) AFTER AN EXTRAORDINARY 22-YEAR CAREER AT NOVARTIS AND MORE THAN 12 YEARS AS A MEMBER OF THE ECN, HARRY KIRSCH WILL RETIRE AND STEP DOWN FROM THE ECN ON MARCH 15, 2026 BASEL, JULY 17, 2025  NOVARTIS ANNOUNCED TODAY THE APPOINTMENT OF MUKUL MEHTA AS THE CHIEF FINANCIAL OFFICER (CFO) AND A MEMBER OF THE EXECUTIVE COMMITTEE OF NOVARTIS (ECN), EFFECTIVE MARCH 16, 2026.

NOVARTIS APPOINTS MUKUL MEHTA AS CHIEF FINANCIAL OFFICER, AS HARRY KIRSCH RETIRES AFTER 22 YEARS WITH THE COMPANY

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Q2 NET SALES GREW +11% (CC 1 , +12% USD) WITH CORE OPERATING INCOME 1 UP +21% (CC, +20% USD) SALES GROWTH DRIVEN BY CONTINUED STRONG PERFORMANCE FROM KISQALI (+64% CC), ENTRESTO (+22% CC), KESIMPTA (+33% CC), SCEMBLIX (+79% CC), LEQVIO (+61% CC) AND PLUVICTO (+30% CC) CORE OPERATING INCOME MARGIN1 REACHED 42.2%, +340 BASIS POINTS (CC), MAINLY DRIVEN BY HIGHER NET SALES Q2 OPERATING INCOME GREW +25% (CC, +21% USD); NET INCOME UP +26% (CC, +24% USD) Q2 CORE EPS 1 GREW +24% (CC, +23% USD) TO USD 2.42 Q2 FREE CASH FLOW 1 OF USD 6.3 BILLION (+37% USD) DRIVEN BY HIGHER NET CASH FLOWS FROM OPERATING ACTIVITIES H1 NET SALES UP +13% (CC, +12% USD) AND CORE OPERATING INCOME UP +24% (CC, +21% USD) Q2 SELECTED INNOVATION MILESTONES: PLUVICTO PHASE III PSMADDITION STUDY POSITIVE READOUT IN PSMA+ MHSPC VANRAFIA (ATRASENTAN) FDA ACCELERATED APPROVAL FOR IGAN OAV101 IT US AND EU SUBMISSIONS FOR SMA VOTOPLAM PHASE II PIVOT-HD STUDY POSITIVE READOUT IN HUNTINGTON'S DISEASE REMIBRUTINIB PHASE II STUDY POSITIVE READOUT IN FOOD ALLERGY INITIATING UP-TO USD 10 BILLION SHARE BUYBACK TO BE COMPLETED BY YEAR-END 2027 FULL-YEAR 2025 GUIDANCE 2 RAISED FOR CORE OPERATING INCOME SALES EXPECTED TO GROW HIGH SINGLE DIGIT (UNCHANGED) CORE OPERATING INCOME EXPECTED TO GROW LOW TEENS (FROM LOW DOUBLE-DIGIT) 1.

NOVARTIS REPORTS STRONG Q2 WITH DOUBLE-DIGIT SALES GROWTH AND CORE MARGIN EXPANSION; RAISES FY 2025 CORE OPERATING INCOME GUIDANCE

BASEL, JULY 8, 2025  NOVARTIS TODAY ANNOUNCED COARTEM (ARTEMETHER-LUMEFANTRINE) BABY HAS BEEN APPROVED BY SWISSMEDIC AS THE FIRST MALARIA MEDICINE FOR NEWBORNS AND YOUNG INFANTS. THE NEW TREATMENT, ALSO KNOWN AS RIAMET BABY IN SOME COUNTRIES, WAS DEVELOPED IN COLLABORATION WITH MEDICINES FOR MALARIA VENTURE (MMV) TO TREAT THE POTENTIALLY DEADLY MOSQUITO-BORNE DISEASE.

NOVARTIS RECEIVES APPROVAL FOR FIRST MALARIA MEDICINE FOR NEWBORN BABIES AND YOUNG INFANTS

THE GCAPTAIN STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF SUSTAINED REMISSION AT WEEK 52 IN ADULTS WITH NEWLY DIAGNOSED OR RELAPSING GCA1 SAFETY IN GCA PATIENTS WAS CONSISTENT WITH KNOWN SAFETY PROFILE OF COSENTYX (SECUKINUMAB)1 EAST HANOVER, N.J. , JULY 3, 2025 /PRNEWSWIRE/ --NOVARTIS TODAY ANNOUNCED TOP-LINE RESULTS FROM THE PHASE III GCAPTAIN STUDY EVALUATING COSENTYX (SECUKINUMAB) IN ADULTS WITH NEWLY DIAGNOSED OR RELAPSING GIANT CELL ARTERITIS (GCA).

NOVARTIS PROVIDES UPDATE ON PHASE III GCAPTAIN STUDY OF COSENTYX IN GIANT CELL ARTERITIS (GCA)

BASEL, JULY 03, 2025  NOVARTIS TODAY ANNOUNCED TOP-LINE RESULTS FROM THE PHASE III GCAPTAIN STUDY EVALUATING COSENTYX (SECUKINUMAB) IN ADULTS WITH NEWLY DIAGNOSED OR RELAPSING GIANT CELL ARTERITIS (GCA).

PROFOUND TO RECEIVE $25M IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS WITH A POTENTIAL VALUE FROM DOWNSTREAM MILESTONES OF $750M PER TARGET

PROFOUND THERAPEUTICS ANNOUNCES MULTI-YEAR STRATEGIC COLLABORATION WITH NOVARTIS TO DISCOVER AND DEVELOP NOVEL THERAPEUTICS FOR CARDIOVASCULAR DISEASE

BASEL, JUNE 25, 2025  NOVARTIS TODAY ANNOUNCED THAT IT HAS SUCCESSFULLY COMPLETED ITS ACQUISITION OF REGULUS THERAPEUTICS INC. (REGULUS). WITH THE COMPLETION OF THE ACQUISITION, SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE (THE SHARES), OF REGULUS, HAVE CEASED TRADING ON THE NASDAQ STOCK MARKET LLC AND REGULUS IS NOW AN INDIRECT WHOLLY OWNED SUBSIDIARY OF NOVARTIS.

NOVARTIS COMPLETES ACQUISITION OF REGULUS THERAPEUTICS

BASEL, JUNE 12, 2025  NOVARTIS ANNOUNCED POSITIVE RESULTS FROM APPULSE-PNH, A PHASE IIIB STUDY EVALUATING THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL MONOTHERAPY FABHALTA(IPTACOPAN) IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) WITH HB LEVELS 10G/DL WHO SWITCHED FROM ANTI-C5 THERAPIES (ECULIZUMAB OR RAVULIZUMAB)1. AFTER 24 WEEKS OF TREATMENT WITH FABHALTA, THE HB LEVEL IMPROVEDON AVERAGE BY 2.01 G/DL (95% CI, 1.74, 2.29) WITH MOST PATIENTS ACHIEVING NORMAL OR NEAR-NORMAL LEVELS 1. DATA WILL BE PRESENTED AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS 2025.

Novartis AG

NVS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Novartis AG

NVS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NVS